Drug Database
PR

prednisolone (Orapred ODT / Predonine)

✓ Approved

Concordia Pharmaceuticals · NR3C1 · 小分子

什么是 prednisolone?

prednisolone 是一种小分子,由Concordia Pharmaceuticals研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Orapred ODT, Predonine
公司Concordia Pharmaceuticals
药物类别小分子
分子靶点NR3C1
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

prednisolone 作用于 1 个分子靶点:

NR3C1nuclear receptor subfamily 3 group C member 1 (GR, GCCR)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

prednisolone 针对 3 个适应症,涉及 3 个治疗领域。

治疗领域疾病/病症分期
Respiratory, thoracic and mediastinal disordersAsthma✓ Approved
Congenital, familial and genetic disordersDuchenne muscular dystrophy✓ Approved
Infections and infestationsBorna virus infection✓ Approved

相关研究文献

PubMedDermatitis : contact, atopic, occupational, drug2026-11-18

Periorbital Allergic Contact Dermatitis to Sodium Metabisulfite in Prednisolone Acetate Ophthalmic Suspension.

Thiraviyarajah Vaish V, Khouri Ashley A, Schlarbaum Jamie P JP

PMID 43046635
阅读全文 →
PubMedEJHaem2026-11-18

How We Use Corticosteroids in Immune Thrombocytopenia.

Gurumurthy Gerard G, Morgan Mervyn M, Provan Drew D, Thachil Jecko J

Corticosteroids remain an important first-line treatment for immune thrombocytopenia (ITP), but their benefits are accompanied by substantial toxicities across various body systems. Their use should therefore be individualised and time-limited. We synthesise current guidance and published evidence concerning the selection of patients for corticosteroids treatment, choice of regimen, prevention and monitoring of treatment-related toxicity, recognition of response and non-response, and structured tapering and discontinuation in adults with ITP. Corticosteroids should be avoided when observation is clinically appropriate and, when prescribed, should have a pre-defined indication, haemostatic control target, expected time to response and stopping date. Accepted first-line regimens include prednisolone at 1-2 mg/kg/day, generally capped at 60-80 mg daily, or high-dose dexamethasone at 40 mg daily for 4 days. A platelet count exceeding 50  ×  109/L within 5-7 days generally identifies an early responder, although a lower count may be adequate when bleeding has resolved and haemostatic safety has been achieved. Responders receiving prednisolone should proceed to dose reduction and complete discontinuation within approximately 6-8 weeks. Patients without an adequate early response should have prednisolone tapered over approximately 2 weeks and with prompt consideration of an alternative or steroid-sparing treatment rather than prolonged dose escalation. Treatment extending beyond 3 weeks, particularly at doses exceeding 5 mg/day of prednisolone equivalent, may confer a risk of hypothalamic-pituitary-adrenal axis suppression and require a more structured taper. Clinicians must balance the therapeutic goals of corticosteroids against the risk of toxicities from their use. The objective of corticosteroid therapy in ITP is to achieve haemostatic safety rather than to elevate or normalise the platelet count. The authors have confirmed clinical trial registration is not needed for this submission.

PMID 43048703
阅读全文 →
PubMedCureus2026-11-18

Early Neonatal Presentation and Management of Diamond-Blackfan Anemia: A Case Report.

de Liz Arcari Henrique H

Diamond-Blackfan anemia (DBA) is a rare congenital red cell aplasia that may present with severe anemia in early infancy. This report describes a case with very early neonatal presentation and a favorable hematologic response to corticosteroid therapy. A term male infant was presented at two days of life with marked pallor, feeding refusal, and severe anemia, with a hemoglobin level of 6.7 g/dL, requiring a red blood cell transfusion. After recurrent episodes of severe anemia, further investigation demonstrated macrocytosis, reticulocytopenia, and a normocellular bone marrow with rare erythroblasts, supporting the diagnosis of DBA. Oral prednisolone was initiated at one month 15 days of age and was associated with subsequent hematologic improvement, allowing gradual dose reduction. At the latest follow-up, the patient was 17 months old and had remained transfusion-independent for 14 months while receiving maintenance prednisolone. This case highlights the importance of considering DBA in neonates with unexplained severe anemia and reticulocytopenia, even in the absence of congenital anomalies. The hematologic response and sustained transfusion independence demonstrate a favorable clinical course following individualized management, with continued follow-up needed to assess long-term response and treatment safety.

PMID 43048496
阅读全文 →
PubMedEuropean journal of rheumatology2026-11-18

Focal Digital Clubbing as an Initial Symptom of Adolescent-Onset Systemic Lupus Erythematosus: A Case Report.

Sato Masayuki M, Nagamori Tsunehisa T, Kurisawa MioJune M, Tsuda Junki J et al.

Digital clubbing is typically linked to pulmonary or cardiovascular diseases. There have been no reported cases of systemic lupus erythematosus (SLE) where the initial complaint was solely foca digital clubbing and a chilblain-like rash on the ngers. A 13-year-old girl experienced digital clubbing for 3 months. Physical examination revealed focal digital clubbing of the thumb, index nger, and middle nger on her right hand, along with slight blotchy erythema assessed as a chilblain-like rash. Laboratory data showed hypocomplementemia and a high anti-double-stranded DNA antibody titer. She was also positive for antiphospholipid antibodies, had prolonged prothrombin time and activated partial thromboplastin time, and elevated anti-prothrombin antibody levels. She was diagnosed with SLE complicated by hypoprothrombinemia associated with lupus anticoagulant. Prednisolone treat ment resolved the digital clubbing and laboratory abnormalities. Digital clubbing may be an initial symptom of SLE. Screening for autoimmune diseases should be considered when a patient presents with digital clubbing not associated with pulmonary or cardiovascular diseases or malignant tumors.   Cite this article as: Sato M, Nagamori T, Kurisawa MJ, Tsuda J, Ishibazawa E, Takahashi S. Focal digital clubbing as an initial symptom of adolescent-onset systemic lupus erythematosus: a case report. Eur J Rheumatol. 2025, 12(4), 0075, doi:10.5152/eurjrheum.2025.24075.

PMID 43049123
阅读全文 →
PubMedSurgical case reports2026-11-18

Acquired Hemophilia A Diagnosed after Repeated Postoperative Bleeding Following Pancreatectomy: A Report of Two Cases.

Hirano Masataka M, Yamada Daisaku D, Akita Hirofumi H, Mukai Yosuke Y et al.

Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder characterized by the development of autoantibodies against factor VIII, resulting in decreased factor VIII activity, and isolated prolongation of activated partial thromboplastin time (APTT). AHA is often diagnosed after the onset of bleeding and may follow a fatal course due to uncontrolled hemorrhage or infectious complications associated with immunosuppressive therapy. Although early diagnosis is essential, the rarity of the disease makes it difficult. We report 2 cases of AHA diagnosed after repeated postoperative bleeding following pancreatectomy. Case 1. An 80-year-old man underwent pancreaticoduodenectomy for ampullary cancer. Postoperatively, he developed recurrent bleeding from the surgical site, requiring repeated interventional radiology procedures until POD 12. Persistent prolongation of APTT that did not correct with transfusion suggested a coagulation disorder. On POD 13, laboratory testing demonstrated decreased factor VIII activity and the presence of a factor VIII inhibitor, confirming the diagnosis of AHA. Despite treatment with recombinant activated factor VII for bleeding, he passed away on POD 34 due to repeated bleeding, infected ascites, and subsequent sepsis. Case 2. An 83-year-old man underwent distal pancreatectomy with celiac axis resection for locally advanced pancreatic cancer. Postoperative anemia progressed with persistent prolongation of APTT despite repeated transfusions. Based on the experience from Case 1, AHA was suspected early. On POD 8, decreased factor VIII activity and the presence of a factor VIII inhibitor confirmed the diagnosis of AHA, and immunosuppressive therapy with prednisolone was initiated immediately. The factor VIII inhibitor became undetectable on POD 36, and the patient was discharged on POD 123. Delayed diagnosis of AHA after invasive surgery such as pancreatectomy may be fatal. AHA should be considered in cases of repeated postoperative bleeding with the prolongation of APTT.

PMID 43047778
阅读全文 →
PubMedJournal of pediatric gastroenterology and nutrition2026-11-17

Treatment of pediatric autoimmune liver disease beyond prednisolone and azathioprine in a cohort of 115 patients.

Korell Marie M, Kramer Miriam M, Poets Alina A, Mutschler Frauke F et al.

Pediatric autoimmune hepatitis (pAIH) is an acute or chronic inflammatory liver disease, caused by a dysregulation of the immune system. Autoimmune sclerosing cholangitis (ASC) additionally affects the bile ducts. Traditional first-line treatment (FLT) consists of prednisolone and azathioprine. If pAIH/ASC remains untreated or biochemical remission (BR) is not achieved, end-stage liver disease develops. We aimed to analyze the 6-months-outcomes of various second- and third-line therapies for pAIH/ASC. This is a retrospective single-center analysis, including all cases of patients with pAIH or ASC between 2000 and 2025. All patients were diagnosed based on published European Society for Paediatric Gastroenterology, Hepatology and Nutrition diagnostic criteria. Of 115 patients with pAIH or ASC, 26 patients required an alternative therapy (altT) other than prednisolone and azathioprine, most of them due to non-BR, including due to non-compliance. The 6-month outcome shows, that tumor necrosis factor (TNF)-alpha inhibitors overall achieved the best results with a BR rate of 40% (n = 2/5). This was closely followed by cyclosporin A (CSA), with a BR rate of 36.4% (n = 4/11), which was the most commonly used drug in our study. Patients with inflammatory bowel disease are significantly more likely to need altT. The overall BR rate 6 months after start of altT is low and decreases with each stage of therapy, the TNF-alpha inhibitors demonstrated the highest BR rate for altT. Non-compliance is a significant problem in general, so it is unclear whether the success of this therapy is solely attributable to the drug's inherent immunomodulatory function or to its controlled administration via intravenous injection. The prospective evaluation of this novel, low-side-effect management option warrants further explorations.

PMID 43042670
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多prednisolone